Literature DB >> 33087301

Receptor binding competition: A paradigm for regulating TGF-β family action.

Erik Martinez-Hackert1, Anders Sundan2, Toril Holien3.   

Abstract

The transforming growth factor (TGF)-β family is a group of structurally related, multifunctional growth factors, or ligands that are crucially involved in the development, regulation, and maintenance of animal tissues. In humans, the family counts over 33 members. These secreted ligands typically form multimeric complexes with two type I and two type II receptors to activate one of two distinct signal transduction branches. A striking feature of the family is its promiscuity, i.e., many ligands bind the same receptors and compete with each other for binding to these receptors. Although several explanations for this feature have been considered, its functional significance has remained puzzling. However, several recent reports have promoted the idea that ligand-receptor binding promiscuity and competition are critical features of the TGF-β family that provide an essential regulating function. Namely, they allow a cell to read and process multi-ligand inputs. This capability may be necessary for producing subtle, distinctive, or adaptive responses and, possibly, for facilitating developmental plasticity. Here, we review the molecular basis for ligand competition, with emphasis on molecular structures and binding affinities. We give an overview of methods that were used to establish experimentally ligand competition. Finally, we discuss how the concept of ligand competition may be fundamentally tied to human physiology, disease, and therapy.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Activin; BMP; Competition; SMAD; Signaling; TGF-β

Mesh:

Substances:

Year:  2020        PMID: 33087301      PMCID: PMC7897244          DOI: 10.1016/j.cytogfr.2020.09.003

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  184 in total

1.  Activin A does not drive post-traumatic heterotopic ossification.

Authors:  Charles Hwang; Chase A Pagani; Nanditha Das; Simone Marini; Amanda K Huber; LiQin Xie; Johanna Jimenez; Susannah Brydges; Wei Keat Lim; Kalyan C Nannuru; Andrew J Murphy; Aris N Economides; Sarah J Hatsell; Benjamin Levi
Journal:  Bone       Date:  2020-06-15       Impact factor: 4.398

2.  Synergistic interaction between Gdf1 and Nodal during anterior axis development.

Authors:  Olov Andersson; Eva Reissmann; Henrik Jörnvall; Carlos F Ibáñez
Journal:  Dev Biol       Date:  2006-03-27       Impact factor: 3.582

3.  Activin A-Induced Cachectic Wasting Is Attenuated by Systemic Delivery of Its Cognate Propeptide in Male Mice.

Authors:  Kelly L Walton; Justin L Chen; Quinn Arnold; Emily Kelly; Mylinh La; Louis Lu; George Lovrecz; Adam Hagg; Timothy D Colgan; Hongwei Qian; Paul Gregorevic; Craig A Harrison
Journal:  Endocrinology       Date:  2019-10-01       Impact factor: 4.736

4.  Inhibin antagonizes inhibition of liver cell growth by activin by a dominant-negative mechanism.

Authors:  J Xu; K McKeehan; K Matsuzaki; W L McKeehan
Journal:  J Biol Chem       Date:  1995-03-17       Impact factor: 5.157

5.  Inhibin is an antagonist of bone morphogenetic protein signaling.

Authors:  Ezra Wiater; Wylie Vale
Journal:  J Biol Chem       Date:  2002-12-18       Impact factor: 5.157

6.  Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.

Authors:  B Dalla Palma; D Guasco; M Pedrazzoni; M Bolzoni; F Accardi; F Costa; G Sammarelli; L Craviotto; M De Filippo; L Ruffini; P Omedè; R Ria; F Aversa; N Giuliani
Journal:  Leukemia       Date:  2015-09-30       Impact factor: 11.528

7.  Bone morphogenetic protein signaling in rotator cuff muscle atrophy and fatty infiltration.

Authors:  Xuhui Liu; Sunil Joshi; Bharat Ravishankar; Dominique Laron; Hubert T Kim; Brian T Feeley
Journal:  Muscles Ligaments Tendons J       Date:  2015-07-03

Review 8.  Smad-dependent and Smad-independent pathways in TGF-beta family signalling.

Authors:  Rik Derynck; Ying E Zhang
Journal:  Nature       Date:  2003-10-09       Impact factor: 49.962

9.  Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors.

Authors:  L Attisano; J Cárcamo; F Ventura; F M Weis; J Massagué; J L Wrana
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

10.  Eukaryotic expression, Co-IP and MS identify BMPR-1B protein-protein interaction network.

Authors:  Jianlei Jia; Jipeng Jin; Qian Chen; Zan Yuan; Haiqin Li; Junhao Bian; Linsheng Gui
Journal:  Biol Res       Date:  2020-05-29       Impact factor: 7.634

View more
  12 in total

1.  Regulation of gene expression in the bovine blastocyst by colony-stimulating factor 2 is disrupted by CRISPR/Cas9-mediated deletion of CSF2RA.

Authors:  Yao Xiao; Kyungjun Uh; Veronica M Negrón-Pérez; Hannah Haines; Kiho Lee; Peter J Hansen
Journal:  Biol Reprod       Date:  2021-05-07       Impact factor: 4.285

2.  Interleukin-1 and Transforming Growth Factor Beta: Commonly Opposing, but Sometimes Supporting, Master Regulators of the Corneal Wound Healing Response to Injury.

Authors:  Steven E Wilson
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-04-01       Impact factor: 4.799

3.  Overexpressed integrin alpha 2 inhibits the activation of the transforming growth factor β pathway in pancreatic cancer via the TFCP2-SMAD2 axis.

Authors:  Hongkun Cai; Feng Guo; Shuang Wen; Xin Jin; Heshui Wu; Dianyun Ren
Journal:  J Exp Clin Cancer Res       Date:  2022-02-22

4.  Competition between type I activin and BMP receptors for binding to ACVR2A regulates signaling to distinct Smad pathways.

Authors:  Szabina Szófia Szilágyi; Ayelet R Amsalem-Zafran; Keren E Shapira; Marcelo Ehrlich; Yoav I Henis
Journal:  BMC Biol       Date:  2022-02-18       Impact factor: 7.431

5.  Circulating TGF-β Pathway in Osteogenesis Imperfecta Pediatric Patients Subjected to MSCs-Based Cell Therapy.

Authors:  Arantza Infante; Leire Cabodevilla; Blanca Gener; Clara I Rodríguez
Journal:  Front Cell Dev Biol       Date:  2022-02-09

Review 6.  Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs.

Authors:  Buel D Rodgers; Christopher W Ward
Journal:  Endocr Rev       Date:  2022-03-09       Impact factor: 25.261

7.  Crystal structures of BMPRII extracellular domain in binary and ternary receptor complexes with BMP10.

Authors:  Jingxu Guo; Bin Liu; Midory Thorikay; Minmin Yu; Xiaoyan Li; Zhen Tong; Richard M Salmon; Randy J Read; Peter Ten Dijke; Nicholas W Morrell; Wei Li
Journal:  Nat Commun       Date:  2022-05-03       Impact factor: 17.694

Review 8.  Accumulated Knowledge of Activin Receptor-Like Kinase 2 (ALK2)/Activin A Receptor, Type 1 (ACVR1) as a Target for Human Disorders.

Authors:  Takenobu Katagiri; Sho Tsukamoto; Mai Kuratani
Journal:  Biomedicines       Date:  2021-06-26

9.  Functionally diverse heteromeric traps for ligands of the transforming growth factor-β superfamily.

Authors:  Ravindra Kumar; Asya V Grinberg; Huiming Li; Tzu-Hsing Kuo; Dianne Sako; Lavanya Krishnan; Katia Liharska; Jia Li; Rosa Grenha; Michelle C Maguire; Steven D Briscoe; R Scott Pearsall; Brantley R Herrin; Rajasekhar N V S Suragani; Roselyne Castonguay
Journal:  Sci Rep       Date:  2021-09-15       Impact factor: 4.379

10.  Targeting TGF-β for treatment of osteogenesis imperfecta.

Authors:  I-Wen Song; Sandesh Cs Nagamani; Dianne Nguyen; Ingo Grafe; Vernon Reid Sutton; Francis H Gannon; Elda Munivez; Ming-Ming Jiang; Alyssa Tran; Maegen Wallace; Paul Esposito; Salma Musaad; Elizabeth Strudthoff; Sharon McGuire; Michele Thornton; Vinitha Shenava; Scott Rosenfeld; Shixia Huang; Roman Shypailo; Eric Orwoll; Brendan Lee
Journal:  J Clin Invest       Date:  2022-04-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.